Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Brainstorm Cell (NQ: BCLI )

2.950 +0.060 (+2.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 32,716
Open 2.880
Bid (Size) 2.850 (3)
Ask (Size) 3.200 (138)
Prev. Close 2.890
Today's Range 2.840 - 2.950
52wk Range 2.650 - 4.460
Shares Outstanding 36,486,180
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap: Brainstorm Cell Q1 Earnings
Brainstorm Cell (NASDAQ:BCLI) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga

Performance

YTD
-29.59%
-29.59%
1 Month
-4.53%
-4.53%
3 Month
-5.45%
-5.45%
6 Month
+4.98%
+4.98%
1 Year
-13.74%
-13.74%

More News

Read More
Brainstorm Cell Earnings Preview
Via Benzinga
Brainstorm Cell: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For March 28, 2022
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Via Benzinga
Preview: Brainstorm Cell's Earnings
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
Via FinancialNewsMedia
Topics Death
Exposures Death
34 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease
Via Benzinga
68 Biggest Movers From Wednesday
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
63 Biggest Movers From Friday
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
22 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Via Benzinga
Exposures COVID-19
Earnings Scheduled For April 26, 2021
Via Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.